Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Medindia1d
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Morningstar4d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Palatin says BMT-801 Phase 2 obesity study met primary endpoint
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
Palatin Technologies, Inc.: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...
Investing7d
Palatin’s obesity drug gains FDA orphan status
The biopharmaceutical firm, which focuses on developing molecules that modulate the melanocortin receptor system, stated that PL7737 could potentially offer a more convenient alternative to the ...
Palatin reports ‘positive’ results from Phase 2 study of PL8177
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
Le Lézard4d
National Triglyceride Alliance Launches to Advance Clinician Education on High Triglycerides and the Importance of Proactive Triglyceride Management
The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing education and awareness about the critical role of triglycerides in metabolic ...